Growth Equity
Monograph Capital
Monograph Capital takes minority stakes in growing companies, usually without full control, from United Kingdom. It states a focus on healthcare & life sciences.
Stated investment criteria
What Monograph Capital says it buys
Read from Monograph Capital’s own website in August 2026. This is what the firm says it buys, not what anyone has recorded it buying, and figures are shown in the currency the firm itself used - nothing here is converted. Every line links to the page it was read from.
| People listed on its team page | 131 |
Source
A stated mandate is a firm’s description of itself and was true of the page on the day it was read; firms widen and narrow what they will look at without updating the site. The team figure counts the people the firm shows on one team page, so it is a floor rather than a headcount: firms that split their team across tabs or load it in pages will read low. Nothing here is a commitment by Monograph Capital to consider any particular business, and nothing on this page is represented as being for sale.
SEC filings
What Monograph Capital has raised
From this firm's own Form D filings. A fund files one within fifteen days of its first sale, under penalty of perjury, which makes these the hardest numbers on the page.
| Vehicles filed | 2 |
| Total capital raised | $154m |
| Largest single vehicle | $154m |
| Filing history | 2021 to 2023 |
| Smallest accepted commitment | None stated |
| Filed from | DELAWARE |
Form D covers US-domiciled vehicles raised from accredited investors. It will not capture a fund raised outside the United States, separately managed accounts, or capital deployed off balance sheet, so treat these as a floor rather than a total.
Regulatory record
How Monograph Capital is registered
Registered with the SEC as an investment adviser, and incorporated in the United Kingdom.
| Adviser status | Exempt reporting adviser |
| Regulatory assets under management | Not reported by an ERA |
| Private funds advised | 2 · $325m gross |
| SEC adviser number | CRD 315988 |
| Companies House number | OC436349 |
| Incorporated | 2021-03-26 |
| Register status | Active |
| Officers on the register | 6 |
An exempt reporting adviser is not required to report regulatory assets under management, so the blank above means the question was not asked rather than that the answer is unknown. Where a figure exists it is the gross asset value of the private funds the firm advises, which is a different and usually larger measure.
Portfolio
Disclosed holdings
Companies Monograph Capital lists on its own website. 9 carry a stated investment year.
| Company | Invested | Years held | Recorded transaction |
|---|---|---|---|
| Ascend | 2021 | 5 | — |
| AviadoBio | 2021 | 5 | — |
| ODAIA | 2023 | 3 | — |
| Sudo | 2023 | 3 | — |
| Autobahn | 2024 | 2 | — |
| Nocion Therapeutics | 2024 | 2 | — |
| Ouro Medicines | 2024 | 2 | — |
| Maxion Therapeutics | 2025 | 1 | — |
| Ollin Biosciences | 2025 | 1 | — |
| Ascend Adv | — | — | — |
| Elevara | — | — | — |
| Gilead | — | — | — |
| Hibio | — | — | — |
| Ollin | — | — | — |
| Prolynx | — | — | — |
| Prolynxinc | — | — | — |
| Regask | — | — | — |
| Sudobio | — | — | — |
| Urogen | — | — | — |
Compiled from Monograph Capital’s published portfolio page. Where a recorded transaction is shown, that company was the target of a reported deal and has most likely already been realised. Nothing here is represented as being for sale.
Valuation context
Transaction values in Healthcare & Life Sciences
What companies have actually sold for in healthcare & life sciences, across 1,263 recorded transactions.
The full healthcare & life sciences picture - most active acquirers, recent transactions and every investor in the sector.
For owners
Own a healthcare & life sciences business?
The investors on this page acquire companies like yours. A confidential valuation costs nothing, commits you to nothing, and nobody is told you asked.
Request a confidential valuationFor investors
Is this Monograph Capital?
Claim this profile to correct anything wrong and tell us what you are looking for. We will send matching opportunities as they arise.
Claim or correct this profileTargeted buyer search
Which hundred of these would actually buy your business?
A researched shortlist with a verified deal-team contact for each, and the reason it is on the list. Fixed fee, from $1,450 - or we make the approach for you and hand you the conversations.
Comparable investors
Similar mandates
Other growth equity investors active in healthcare & life sciences.